The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy

Documenti analoghi

• An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
  di: Wu, Shang-Gin, et al.
  Pubblicazione: (2020)
• The impact of rescue or maintenance therapy with EGFR TKIs for Stage IIIb-IV non-squamous non-small-cell lung cancer patients requiring mechanical ventilation
  di: Hsia, Te-Chun, et al.
  Pubblicazione: (2014)
• T790M and acquired resistance of EGFR TKI: a literature review of clinical reports
  di: Ma, Chunyan, et al.
  Pubblicazione: (2011)
• Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
  di: Chen, Hung-Jen, et al.
  Pubblicazione: (2020)
• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  di: Tseng, Jeng-Sen, et al.
  Pubblicazione: (2016)